Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01418885
  4. Details
NCT01418885 Clinical Trial

Cognitive Impairment , Neuroimaging and Inflammatory Markers in Patients With Subcortical Ischemic Vascular Disease

Other Generalized Ischemic Cerebrovascular Disease Clinical Trial

Official title:
Correlation Exploration Between Cognitive Impairment and Neuroimaging and Inflammatory Markers in Patients With Subcortical Ischemic Vascular Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT01418885
Other study ID # dongyanhong85989995
Secondary ID Hebei general ho
Status Active, not recruiting
Phase N/A
First received August 16, 2011
Last updated August 16, 2011
Start date September 2010
Est. completion date December 2011

Study information
Verified date August 2010
Source Hebei General Hospital
Contact n/a
Is FDA regulated No
Health authority China: Ministry of Health
Study type Observational

Clinical Trial Summary

SIVD is characterised by extensive cerebral white matter lesions (WML) and lacunar infarcts in deep grey and white matter structures. The relationship between SIVD and cognition is unclear, in part because of methodological inconsistencies across studies.

Diffusion tensor imaging (DTI) is a non-invasive water diffusion technique and can be used for quantitatively measuring the degree and directionality of the displacement distribution of water molecules. 1H magnetic resonance spectroscopy (1H-MRS) is a valuable tool for the assessment of several biochemical compounds in the brain in vivo, such as N-acetylaspartate (NAA), myoinositol (mI), Choline (Cho) and Creatine (Cr). There were few reports considering the relationship among MRS, DTI and cognitive impairment of SIVD. Combining MRS with DTI may provide valuable information about the pathophysiological changes underlying DTI abnormalities and help us to better understand the SIVD process. It has been proposed that the pathogenesis of SIVD related to cerebral small vessel disease caused by various mechanisms. Inflammation plays an important role in the pathogenesis of SIVD. The examination of inflammatory markers in relation to VaD might be benefit to early treatment.

In this study we applied neuropsychological tests, conventional MRI scanning, DTI, 1H-MRS techniques and inflammatory markers to estimate neuropsychological profile and white matter characteristics of imaging in patients with SIVD. Moreover, the relationship between WML and cognitive function impairment was also investigated. It could be possible to gain reliable data which is benefit to early diagnosis and treatment of cognitive impairment in SIVD.

Description:

1. Contributions of white matter lesions to cognitive impairment in patients with subcortical ischemic vascular disease

1. Extensive neuropsychological tests including MMSE and covering 5 cognitive domains including memory, executive, visuospatial, attention and language function would be performed on patients with SIVD and normal elderly controls matched in age and gender. The patients would be divided into VaD and VCIND group.

2. Age-related white matter change rating scale, which is a visual rating scale developed by Wahlund, would be used to qualitative measure and locate the WML.

3. Correlation analysis and hierarchical multiple regression analysis would be used to examine the relationship between general cognitive function and WML.

2. Evaluation of microstructural white matter lesions in patients with subcortical vascular cognitive impairment using diffusion tensor imaging

1. SIVD patients divided into VaD and VCIND group and normal elderly controls matched in age and gender would be recruited. DTI images would be acquired, and fractional anisotropy (FA), mean diffusivity (MD) of normal-appearing white matter in cerebral lobes would be determined.

2. These diffusion measurements were compared across the 3 groups, and significant differences would be further performed for correlation with tests of comprehensive cognitive function.

3. Evaluation of the lesions in thalamus and paraventricular white matter region in SIVD patients using 1H magnetic resonance spectroscopy and diffusion tensor imaging

1. SIVD patients divided into VaD and VCIND group and normal elderly controls matched in age and gender would be recruited. The quantitative analysis of N-acetylaspartate (NAA), myoinositol (mI), Choline (Cho) and Creatine (Cr) resonance signals in region of interests located in thalamus and paraventricular white matter region would be measured. Ratios of NAA/ Cr, mI/ Cr and Cho/ Cr would be calculated in three groups.

2. Conventional MRI and DTI scanning were received, FA and MD values of white matter in the same bilateral regions would be measured respectively.

3. These diffusion measurements would be compared across the 3 groups, and significant differences would be further performed for correlation with tests of comprehensive cognitive function.

4. Clinical significance of serum inflammatory markers in SIVD patients

1. SIVD patients divided into VaD and VCIND group and normal elderly controls matched in age and gender would be recruited. The serum levels of sCD40L, IL-6, hsCRP were detected by enzyme linked immunosorbent assay (ELISA) and fixed time nephelometry methods in all subjects, respectively.

2. The relationship would be described among these inflammatory factors and WML, cognitive impairment in patients with SIVD.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 100
Est. completion date December 2011
Est. primary completion date September 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Clinical diagnosis of subcortical ischemic vascular disease

- Must exist cognitive impairment

Exclusion Criteria:

- serious dementia could not speak , listen and white

- other diseases which might cause dementia

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Locations
Country Name City State
China Yanhongdong Shijiazhuang Hebei

Sponsors (1)
Lead Sponsor Collaborator
Hebei General Hospital

Country where clinical trial is conducted

China, 

External Links